M-S (Synthetics Pre-2010)

SYNTHETICS and COMPOUNDS THAT AFFECT the ENDOCANNABINOID SYSTEM Pre-2010

MARINOL / DRONABINOL (Synthetic THC, CB1 and CB2 Agonist)
MDA-7 (Strong CB2 Agonist)
MDA-19 (Strong CB2 Agonist)
NABILONE / CESAMET (Synthetic THC, CB1 and CB2 Agonist)
O-1812 (Stable Analog of Anandamide)
O-1918 (GPR18 Antagonist)
O-1966 (CB2 Agonist)
O-2050 (CB1 Antagonist)
OMDM-1 (Blocks Re-uptake of Endocannabinoids)
OMDM-2 (Blocks Re-uptake of Endocannabinoids)
PF-3845 (Blocks Breakdown of Anandamide)
RIMONABANT / ACOMPLIA / SR141716 / SR1 (CB1 and CB2 Antagonist, Failed Weight Loss Drug [1994-2009])
R(+)-METHANANANDAMIDE / AM-356 (More Stable Anandamide Analog [1994-2009])
RWJ-400065 (CB2 Agonist)
SAB-378 (Activates Peripheral CB1 and CB2 Receptors, No ‘High’)
SPICE-NEWS (Various Synthetic Cannabinoid Mixtures, See Also AM, HU, JWH and CP series)
SR-144528
SURINABANT / SR 147778
top


MARINOL / DRONABINOL
Cannabinoids (encyclopedia entry) http://www.chemie.de/lexikon/e/Cannabinoids/
CANNABIS AND MARINOL IN THE TREATMENT OF MIGRAINE HEADACHE (letter-undated) http://www.druglibrary.org/schaffer/hemp/migrn2.htm
Evaluation of the Use of Both Marijuana and THC in Cancer Patients for the Relief of Nausea and Vomiting Associated With Cancer Chemotherapy After Failure of Conventional Anti-Emetic Therapy: Efficacy and Toxicity (full–1983) http://www.gacareproject.com/wp-content/uploads/2014/02/Binder1.pdf
Dronabinol enhancement of appetite in cancer patients (abst–1990) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=149
Recent clinical experience with dronabinol (abst–1991) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=90
Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting (abst-1991) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=28
Chronic Migraine Headache: five cases successfully treated with Marinol and/or illicit cannabis (abst-1991) http://www.druglibrary.org/schaffer/hemp/migrn1.htm
Dronabinol stimulates appetite and causes weight gain in HIV patients (abst–1992) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=20
Dronabinol effects on weight in patients with HIV infection (abst–1992) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=45
Effect of dronabinol on nutritional status in HIV infection (abst–1993) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=150
Treatment of spasticity in spinal cord injury with dronabinol, a tetrahydrocannabinol derivative (abst–1995) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=112
Marinol vs. Marijuana: Politics, Science, and Popular Culture (article–1997) http://members.iowatelecom.net/sharkhaus/marinol_long.html
Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease (abst–1997) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=59
Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (dronabinol) (abst-1997) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=35
Abuse potential of dronabinol (Marinol) (abst–1998) http://www.ncbi.nlm.nih.gov/pubmed/9692381
Effects of smoked cannabis and oral d9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy (full–2001) http://www.cannabis-med.org/data/pdf/2001-01-2.pdf
top
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review (full-2001) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC34325/?tool=pmcentrez
Chapter 3: Cannabis and Marinol Compared (book excerpt–2001) http://www.or-coast.net/contigo/PDF%201%20Files/chpt_3.pdf
Healing Haze? (news-2001) http://www.scientificamerican.com/article.cfm?id=healing-haze
The Role of Cannabis and Cannabinoids in Pain Management (full–2002) http://www.humanhemphealth.ca/Russo-AAPM_chapter.pdf
Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease (abst-2002) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=116
Cannabis and the brain (full-2003) http://brain.oxfordjournals.org/cgi/content/full/126/6/1252
Cannabinoid rotation in a young woman with chronic cystitis (abst-2003) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=115
Safety and efficacy of dronabinol in the treatment of agitation in patients with Alzheimer’s disease A retrospective chart review (abst–2003) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=61
On the application of cannabis in paediatrics and epileptology (abst–2003) http://www.ncbi.nlm.nih.gov/pubmed/15159680
Open-label study of dronabinol in the treatment of refractory agitation in Alzheimer’s disease: a pilot study (abst-2003) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=92
Therapeutic potential of cannabinoids in CNS disease (abst–2003) http://www.ncbi.nlm.nih.gov/pubmed/12617697
Marinol Death Sentence: Oregon Man Denied Liver Transplant Because of Prescription — He’s Not the Only One (news–2003) http://stopthedrugwar.org/chronicle-old/299/notransplant.shtml
MARINOL® (Dronabinol) Capsules (monograph–2004) http://www.fda.gov/ohrms/dockets/dockets/05n0479/05N-0479-emc0004-04.pdf
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial (full-2004) http://www.bmj.com/cgi/content/full/329/7460/253
A Novel Intervention for the Treatment of Gout in an Elderly Rehabilitation Patient in Whom Conventional Treatment was Ineffective (full–2004) http://www.medicine.virginia.edu/clinical/departments/physical-medicine-rehabilitation/Gout-page
Cannabinoid agonists in the treatment of blepharospasm–a case report study (abst-2004) http://www.ncbi.nlm.nih.gov/pubmed/15159681
Adverse Event Reporting System – Marinol/ Dronabinol (full–2005) http://medicalmarijuana.procon.org/sourcefiles/marinol.pdf
Marinol vs Natural Cannabis (full-2005) http://www.norml.org/pdf_files/NORML_Marinol_vs_Natural_Cannabis.pdf
Dronabinol can’t replace medical marijuana (article–2005) http://www.managedcaremag.com/linkout/2005/8/58
top
Testimony of Terry Jacobs to FDA – why he prefers for medical marijuana to Marinol (testimony–2005) http://www.examiner.com/examiner/x-19678-Cannabis-Revolution-Examiner~y2009m11d5-Testimony-of-Terry-Jacobs-to-FDA–why-he-prefers-for-medical-marijuana-to-Marinol
Cannabinoids In Medicine: A Review Of Their Therapeutic Potential (full–2006) http://www.doctordeluca.com/Library/WOD/WPS3-MedMj/CannabinoidsMedMetaAnalysis06.pdf
WO 2006063109 A2 – Room-temperature stable dronabinol formulations (full–2006) http://www.google.com/patents/WO2006063109A2?cl=en
Dronabinol reduces signs and symptoms of idiopathic intracranial hypertension : a case report (abst-2006) http://www.liebertonline.com/doi/abs/10.1089/jop.2006.22.68
Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases (abst-2006) http://www.ncbi.nlm.nih.gov/pubmed/16408219
Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study (abst–2006) http://www.ncbi.nlm.nih.gov/pubmed/16918762
Cannabis Chemicals May Alleviate Post-Eating Stomach Cramps (news–2006) http://www.bio-medicine.org/medicine-news/Cannabis-Chemicals-May-Alleviate-Post-Eating-Stomach-Cramps-15219-1/
Big Pharma’s Strange Holy Grail: Cannabis Without Euphoria? (news–2006) http://www.mapinc.org/drugnews/v06.n899.a05.html
ACG: Cannabinoid Activator Mellows Out Colon (news–2006) http://www.medpagetoday.com/MeetingCoverage/ACG/4410
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions (full–2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2013961/pdf/0707261a.pdf
Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study (full–2007) http://ajpgi.physiology.org/cgi/content/full/293/1/G137
US Patent Application 20070020193 – Dronabinol compositions and methods for using same (full–2007) http://www.freshpatents.com/Dronabinol-compositions-and-methods-for-using-same-dt20070125ptan20070020193.php
Letter: Cannabinoid medicines and the need for the scientific method (letter–2007) http://www.cannabis-med.org/data/pdf/en_2007_02_3.pdf
Dronabinol an effective appetite stimulant? A pilot study (abst–2007) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=188
Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis (abst–2007) http://www.ncbi.nlm.nih.gov/pubmed/17566383
Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting (abst-2007) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=191
top
Dronabinol and marijuana in HIV-positive marijuana smokers: caloric intake, mood, and sleep (abst-2007) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=190
Dronabinol and retinal hemodynamics in humans (abst–2007) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=202
Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances (abst-2007) http://www.ncbi.nlm.nih.gov/pubmed/17868014
Anorexia of aging in long term care: is dronabinol an effective appetite stimulant?–a pilot study (abst–2007) http://www.ncbi.nlm.nih.gov/pubmed/17435963
Appetite stimulants in cystic fibrosis: a systematic review (abst–2007) http://www.ncbi.nlm.nih.gov/pubmed/18001374
Cannabinoids in the management of difficult to treat pain (full–2008) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/?tool=pmcentrez
US Patent EP 2046290 A2 – Aqueous dronabinol formulations (full–2008) http://www.google.com/patents/EP2046290A2?cl=en
Improvement in Refractory Obsessive Compulsive Disorder With Dronabinol (letter-2008) http://ajp.psychiatryonline.org/article.aspx?articleID=99760
Current Status of Cannabis Treatment of Multiple Sclerosis with an Illustrative Case Presentation of a Patient with MS, Complex Vocal Tics, Paroxysmal Dystonia, and Marijuana Dependence Treated with Dronabinol (abst-2008) http://www.ncbi.nlm.nih.gov/pubmed/18496477
Medical use of cannabinoids does not cause an increase in serious adverse health effects (news-2008) http://www.cannabis-med.org/english/bulletin/ww_en_db_cannabis_artikel.php?id=272
Deaths from Marijuana v. 17 FDA-Approved Drugs (full–2009) http://medicalmarijuana.procon.org/view.resource.php?resourceID=145
Emerging strategies for exploiting cannabinoid receptor agonists as medicines (full–2009) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697681/
THC can improve symptoms of schizophrenia (article–2009) http://www.cannabis-med.org/data/pdf/en_2009_04_1_0.pdf
Cluster attacks responsive to recreational cannabis and dronabinol (abst–2009) http://www.ncbi.nlm.nih.gov/pubmed/19220500
Effects of {Delta}9-tetrahydrocannabinol on reward and anxiety in rats exposed to chronic unpredictable stress (abst–2009) http://www.unboundmedicine.com/medline/ebm/record/19406854/abstract/Effects_of_%7BDelta%7D9_tetrahydrocannabinol_on_reward_and_anxiety_in_rats_exposed_to_chronic_unpredictable_stress_
Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia (abst–2009) http://www.unboundmedicine.com/medline/ebm/record/19440079/abstract/
Neurobiology and Systems Physiology of the Endocannabinoid System (abst–2009) https://www.thieme-connect.com/ejournals/abstract/10.1055/s-0029-1216346
Does the Pot Pill Work? (news-2009) http://www.cbsnews.com/stories/2009/08/03/health/main5209380.shtml
top
The FDA has written documentation that patients can overdose on Marinol and that it can be lethal (news–2009) http://www.examiner.com/examiner/x-19678-Cannabis-Revolution-Examiner~y2009m10d23-The-FDA-has-written-documentation-that-patients-can-overdose-on-Marinol-and-that-it-can-be-lethal


MDA-7
MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models (full–2008) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597252/


MDA-19
Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain (abst–2008) http://www.ncbi.nlm.nih.gov/pubmed/18666769


NABILONE / CESAMET
Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A (full–2001) http://www.nature.com/npp/journal/v24/n2/full/1395605a.html
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study (abst-2001) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=54
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat (full–2002) http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1573125&tool=pmcentrez
Cannabinoids and multiple sclerosis (abst-2002) http://www.ncbi.nlm.nih.gov/pubmed/12182963
Cannabinoid rotation in a young woman with chronic cystitis (abst-2003) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=115
Therapeutic potential of cannabinoids in CNS disease (abst–2003) http://www.ncbi.nlm.nih.gov/pubmed/12617697
Nabilone Could Treat Chorea and Irritability in Huntington’s Disease (letter–2006) http://neuro.psychiatryonline.org/article.aspx?articleid=102920
top
Nabilone significantly reduces spasticity-related pain (abst–2006) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=200
The synthetic cannabinoid nabilone improves pain and symptom management in cancer patients (abst-2006) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=177
Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : A double-blind placebo-controlled cross-over trial (abst-2006) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=200
Synthetic cannabinomimetic nabilone on patients with chronic pain (abst–2006) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=197
The synthetic cannabinoid nabilone improves pain and symptom management in cancer patients (abst-2006) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=177
Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : A double-blind placebo-controlled cross-over trial (abst-2006) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=200
The synthetic cannabinoid nabilone improves pain and symptom management in cancer patients (abst–2006) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=177
Nabilone improves pain and symptom management in cancer patients (abst-2006) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=177
Synthetic cannabinomimetic nabilone on patients with chronic pain (abst–2006) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=197
A Look At FDA-OK’d ‘Marijuana’ Drug (news–2006) http://www.cbsnews.com/stories/2006/05/18/health/webmd/main1632561.shtml
2nd synthetic marijuana drug OK’d for chemo effects (news–2006) http://www.usatoday.com/news/health/2006-05-16-marijuana-drug_x.htm
Cesamet, THC and chemotherapy (news–2006) http://www.sciencebase.com/science-blog/cesamet-thc.html
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions (full–2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2013961/pdf/0707261a.pdf
Cesamet (nabilone) capsule (info page–2007) http://dailymed.nlm.nih.gov/dailymed/mobile/drugInfo.cfm?id=4474
Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis (abst–2007) http://www.ncbi.nlm.nih.gov/pubmed/17566383
Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances (abst-2007) http://www.ncbi.nlm.nih.gov/pubmed/17868014
Synthetic Cannabis for Fibromyalgia Pain? (news–2007) http://www.healthcentral.com/chronic-pain/c/5949/16104/fm-pain
Nabilone relieves many advanced Ca symptoms (news–2007) http://www.highbeam.com/doc/1G1-178441488.html
Cannabinoids in the management of difficult to treat pain (full–2008) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/?tool=pmcentrez
top
Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study (full–2008) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213874/?tool=pubmed
Nabilone for the treatment of pain in fibromyalgia (abst–2008) http://www.ncbi.nlm.nih.gov/pubmed/17974490
Nabilone for the treatment of paraneoplastic night sweats: a report of four cases (abst–2008) http://www.ncbi.nlm.nih.gov/pubmed/18715188
Science: Nabilone effective in the treatment of night sweats of four patients with advanced cancer (news–2008) http://www.cannabis-med.org/english/bulletin/ww_en_db_cannabis_artikel.php?id=277
Marijuana Derivative Called Effective in Fibromyalgia (news–2008) http://www.medpagetoday.com/Rheumatology/Fibromyalgia/8377
Cannabinoid may be useful for pain management in fibromyalgia (news–2008) http://www.rheumatologyupdate.com.au/news/cannabinoid-may-be-useful-for-pain-management-in-f
Marijuana-Based Drug Reduces Fibromyalgia Pain, Study Suggests (news–2008) http://www.sciencedaily.com/releases/2008/02/080217214547.htm
Two New Approaches for Fibromyalgia (news–2008) http://www.health-and-age.org/health-topics/2008/2/27/two-new-approaches-for-fibromyalgia.html
Cannabinoids, Endocannabinoids, and Related Analogs in Inflammation (full-2009) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2664885/?tool=pmcentrez
Emerging strategies for exploiting cannabinoid receptor agonists as medicines (full–2009) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697681/
The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD) (full-2009) http://onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2008.00071.x/full
Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside (full–2009) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755639/
A pilot study using nabilone for symptomatic treatment in Huntington’s disease (abst–2009) http://www.unboundmedicine.com/medline/ebm/record/19845035/abstract/A_pilot_study_using_nabilone_for_symptomatic_treatment_in_Huntington%27s_disease_
ANXYIOLYTIC EFFECT OF AN ORAL CANNABINOID IN PATIENTS WITH ANXIETY (abst–2009) http://www.efic-congress.org/showabstract.php?abstract=695
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression (abst–2009) http://www.ncbi.nlm.nih.gov/pubmed/19285266
top
BENEFICIAL EFFECT OF AN ORAL CANNABINOID IN PATIENTS WITH IBS (abst–2009) http://www.efic-congress.org/showabstract.php?abstract=696
Treatment of Refractory Post Herpetic Neuralgia with Nabilone (abst–2009) http://www.efic-congress.org/showabstract.php?abstract=699
Evalutation of nabilone as an adjunctive to gabapentin in the management of multiple sclerosis-induced neuropathic pain: An Interim Analysis (abst–2009) http://www.efic-congress.org/showabstract.php?abstract=697
Opiate sparing effects of cannabinoid in refractory CRPS patients (abst–2009) http://www.efic-congress.org/showabstract.php?abstract=698


O-1812
A Comparison of the Discriminative Stimulus Effects of Δ⁹-Tetrahydrocannabinol and O-1812, a Potent and Metabolically Stable Anandamide Analog, in Rats (abst–2004) http://www.ncbi.nlm.nih.gov/pubmed/15301634
Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 -/-mice (full–2008) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2751575/


O-1918
Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor (full–2003) http://molpharm.aspetjournals.org/content/63/3/699.long
Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries (full–2004) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574972/
Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor (full–2006) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1616976/
Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery (abst–2007) http://www.ncbi.nlm.nih.gov/pubmed/17921818
top


O-1966
CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury (full-2009) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319431/


O-2050
Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor ‘silent antagonist (abst–2005) http://www.sciencedirect.com/science/article/pii/S0014299905012197


OMDM-1
Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility (full–2005) http://molehr.oxfordjournals.org/content/11/1/21.full


OMDM-2
Novel selective and metabolically stable inhibitors of anandamide cellular uptake (abst–2003) http://www.ncbi.nlm.nih.gov/pubmed/12732359
In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake (abst–2004) http://www.ncbi.nlm.nih.gov/pubmed/14744610
Development of the first potential covalent inhibitors of anandamide cellular uptake (abst–2006) http://www.ncbi.nlm.nih.gov/pubmed/16570928
Effects of endocannabinoid neurotransmission modulators on brain stimulation reward (abst–2006) http://www.ncbi.nlm.nih.gov/pubmed/16953388
STUDIES OF ANANDAMIDE ACCUMULATION INHIBITORS IN CEREBELLAR GRANULE NEURONS (full–2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2248273/
The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet (full–2008) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275439/?tool=pubmed
Neuronal and glial alterations in the cerebellar cortex of maternally deprived rats: gender differences and modulatory effects of two inhibitors of endocannabinoid inactivation (full–2008) http://onlinelibrary.wiley.com/doi/10.1002/dneu.20672/pdf
Gender-dependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: a possible role for the endocannabinoid system (full–2008) http://onlinelibrary.wiley.com/doi/10.1002/dneu.20666/pdf
top


PF-3845
Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain (full–2009) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692831/


RIMONABANT / ACOMPLIA / SR141716 / SR1
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor (abst–1994) http://www.ncbi.nlm.nih.gov/pubmed/8070571
The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat (abst–1995) http://www.ncbi.nlm.nih.gov/pubmed/7488739
Cannabinoids enhance human B-cell growth at low nanomolar concentrations (abst–1995) http://www.ncbi.nlm.nih.gov/pubmed/7544292
Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist (abst–1995) http://www.ncbi.nlm.nih.gov/pubmed/7776817
Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A (abst–1995) http://www.ncbi.nlm.nih.gov/pubmed/7498260
Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock (abst–1997) http://www.ncbi.nlm.nih.gov/pubmed/9394002
SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset (abst–1998) http://www.ncbi.nlm.nih.gov/sites/entrez/10065938?dopt=Abstract&holding=f1000,f1000m,isrctn
Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors (abst–1999) http://link.springer.com/article/10.1007%2Fs002130050953
The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2 (full–2001) http://www.nature.com/npp/journal/v24/n2/full/1395605a.html
Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon (full–2003) http://ajpgi.physiology.org/content/286/1/G110.full?sid=fc6948f0-78cf-405c-981b-afaa05ee417c
Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study (abst-2003) http://www.ncbi.nlm.nih.gov/pubmed/14746372?dopt=Abstract
Evidence for an Interaction between CB1 Cannabinoid and Melanocortin MCR-4 Receptors in Regulating Food Intake (full–2004) http://press.endocrine.org/doi/full/10.1210/en.2004-0059
top
Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries (full–2004) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574972/
A Comparison of the Discriminative Stimulus Effects of Δ⁹-Tetrahydrocannabinol and O-1812, a Potent and Metabolically Stable Anandamide Analog, in Rats (abst–2004) http://www.ncbi.nlm.nih.gov/pubmed/15301634
Overeating, Alcohol and Sucrose Consumption Decrease in Cb1 Receptor Deleted Mice (abst–2004) http://www.ncbi.nlm.nih.gov/pubmed/12770700
Ethanol Induces Higher Bec in Cb1 Cannabinoid Receptor Knockout Mice While Decreasing Ethanol Preference (full–2005) http://alcalc.oxfordjournals.org/content/40/1/54.long
Activation of the Peripheral Endocannabinoid System in Human Obesity (full–2005) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228268/?tool=pmcentrez
Enhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear (full-2005) http://www.nature.com/npp/journal/v30/n3/full/1300655a.html
Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma (full–2005) http://www.sciencedirect.com/science/article/pii/S0014579305013803
Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility (full–2005) http://molehr.oxfordjournals.org/content/11/1/21.full
The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors (abst–2005) http://www.sciencedirect.com/science/article/pii/S0014299905013178
The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors (abst–2005) http://www.ncbi.nlm.nih.gov/pubmed/16438952
The Cannabinoid Cb1 Receptor Antagonist Rimonabant Attenuates the Hypotensive Effect of Smoked Marijuana in Male Smokers (full–2006) http://www.ahjonline.com/article/S0002-8703%2805%2901013-6/fulltext
Weight Control in Individuals With Diabetes (full–2006) http://care.diabetesjournals.org/content/29/12/2749.full?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=cannabis&searchid=1&FIRSTINDEX=2000&resourcetype=HWCIT
Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor (full–2006) http://molpharm.aspetjournals.org/content/70/1/41.long
Anxiolytic-like properties of the anandamide transport inhibitor AM404 (full–2006) http://www.nature.com/npp/journal/v31/n12/full/1301061a.html
top
Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor (full–2006) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1616976/
Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats (abst–2006) http://www.ncbi.nlm.nih.gov/pubmed/16491428
Effects of endocannabinoid neurotransmission modulators on brain stimulation reward (abst–2006) http://www.ncbi.nlm.nih.gov/pubmed/16953388
Big Pharma’s Strange Holy Grail: Cannabis Without Euphoria? (news–2006) http://www.mapinc.org/drugnews/v06.n899.a05.html
Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia (full–2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771679/?tool=pubmed
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions (full–2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2013961/pdf/0707261a.pdf
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users (full-2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689519/?tool=pubmed
Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells (full-2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267266/?tool=pmcentrez
CB1 receptors mediate the analgesic effects of cannabinoids on colorectal distension-induced visceral pain in rodents (full–2007) http://www.jneurosci.org/content/29/5/1554.long
Cardiovascular Abnormalities in Cirrhosis: the Possible Mechanisms (full-2007) http://journals.tums.ac.ir/upload_files/pdf/_/6670.pdf
Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies (abst–2007) http://www.ncbi.nlm.nih.gov/pubmed/17507169
Pharmacological analysis of cannabinoid-induced inhibition of gastric mucosal damage and gastric motility (abst – 2007) https://www.thieme-connect.com/ejournals/abstract/10.1055/s-2007-982722
European watchdog warns about dangers of Acomplia (news–2007) http://www.news-medical.net/news/2007/07/21/27891.aspx
Three Long-Term Diet Pills Show Poor Performance, Study Suggests (news–2007)  http://www.sciencedaily.com/releases/2007/11/071116094804.htm
FDA Advisory Panel Rejects Obesity Drug (news–2007) http://firstwatch.jwatch.org/cgi/content/full/2007/615/2?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=2800&resourcetype=HWCIT
Differential response to a selective cannabinoid receptor antagonist (SR141716: rimonabant) in female mice from lines selectively bred for high voluntary wheel-running behaviour (abst–2008) http://www.ncbi.nlm.nih.gov/pubmed/19020416
Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716) (abst–2008) http://www.frontiersin.org/publications/18654765
top
Risk of psychiatric side effects is approximately doubled in patients taking Acomplia (news-2008) http://www.medicinenews.net/article/risk-of-psychiatric-side-effects-is-approximately-doubled-in-patients-taking-acomplia
Caution Urged With New Anti-Obesity Drug In Kids (news–2008) http://www.sciencedaily.com/releases/2008/05/080507133326.htm
Weeding out the highs of medical marijuana (news–2008) http://www.alphagalileo.org/ViewItem.aspx?ItemId=4726&CultureCode=en
Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions (full–2009) http://www.nature.com/ijo/journal/v33/n9/full/ijo2009132a.html
The psychiatric side-effects of rimonabant (full–2009) http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462009000200012&lng=en&nrm=iso&tlng=en
Effects of the cannabinoid CB1 receptor antagonist rimonabant on distinct measures of impulsive behavior in rats (full–2009) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1915592/?tool=pubmed
The endocanabinnoid system and diabetes – critical analyses of studies conducted with rimonabant (full-2009) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770455/?tool=pmcentrez
Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists (full–2009) http://www.eje-online.org/cgi/content/full/161/5/655?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=160&resourcetype=HWCIT
Evaluation of Prevalent Phytocannabinoids in the Acetic Acid Model of Visceral Nociception (full–2009) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2765124/?tool=pubmed
Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology (full-2009) http://www.biomedcentral.com/1471-230X/9/75
Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death (full-2009) http://onlinelibrary.wiley.com/doi/10.1111/j.1742-4658.2008.06765.x/full
The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation (full–2009) http://www.nature.com/ijo/journal/v33/n2s/full/ijo200967a.html
Endocannabinoids and cardiovascular prevention: real progress? (link to PDF–2009) http://www.pagepress.org/journals/index.php/hi/article/view/1162
Impairments in Endocannabinoid Signaling and Depressive Illness (abst-1st page–2009) http://jama.jamanetwork.com/article.aspx?articleid=183558
Neurobiology and Systems Physiology of the Endocannabinoid System (abst–2009) https://www.thieme-connect.com/ejournals/abstract/10.1055/s-0029-1216346
top
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression (abst–2009) http://www.ncbi.nlm.nih.gov/pubmed/19285266
Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients (abst–2009) http://www.ncbi.nlm.nih.gov/pubmed/19384170
Cannabinoid receptor activation reverses kainate-induced synchronized population burst firing in rat hippocampus (abst–2009) http://www.frontiersin.org/integrative_neuroscience/10.3389/neuro.07.013.2009/abstract
Effects of cannabinoid drugs on the reinforcing properties of food in gestationally undernourished rats (abst–2009) http://www.ncbi.nlm.nih.gov/pubmed/19602424


R(+)-METHANANANDAMIDE / AM-356
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability (abst–1994) http://www.ncbi.nlm.nih.gov/pubmed/8021930
Cannabinoids might reduce spasticity in multiple sclerosis (full–2000) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1117698/?tool=pmcentrez
Protective effects of cannabinoid receptor ligands analogous to anandamide against cocaine toxicity (abst–2001) http://www.ncbi.nlm.nih.gov/pubmed/11828716
Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: a possible mechanism (abst–2002) http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Retrieve&list_uids=12428277&dopt=abstractplus
Anandamide and R-(+)-methanandamide prevent development of ischemic and reperfusion arrhythmia in rats by stimulation of CB2-receptors (abst–2002) http://www.ncbi.nlm.nih.gov/pubmed/12227101
CANNABINOIDS ALTER RECOGNITION MEMORY IN RATS (full–2003) http://www.if-pan.krakow.pl/pjp/pdf/2003/5_903.pdf
Up-Regulation of Cyclooxygenase-2 Expression Is Involved in R(_)-Methanandamide-Induced Apoptotic Death of Human Neuroglioma Cells (full–2004) http://molpharm.aspetjournals.org/content/66/6/1643.full.pdf+html
Cannabinoid Receptor-Mediated Apoptosis Induced by R(+)-Methanandamide and Win55,212-2 Is Associated with Ceramide Accumulation and p38 Activation in Mantle Cell Lymphoma (full–2006) http://molpharm.aspetjournals.org/content/70/5/1612.full
R(+)-methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cells (full–2006) http://jpet.aspetjournals.org/content/316/3/1219.long
Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain (full–2006) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1769340/?tool=pubmed
R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells (abst–2006) http://www.springerlink.com/content/l403431l1728x733/
top
Differential mechanisms mediating depressor and diuretic effects of anandamide (abst–2006) http://www.ncbi.nlm.nih.gov/pubmed/17053550
Loss of cannabinoid receptor 1 accelerates intestinal tumor growth (full–2008) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2561258/?tool=pubmed
Cannabinoids enhance gastric X/A-like cells activity (full–2008) http://czasopisma.viamedica.pl/fhc/article/view/4436/3691
Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation (full–2008) http://onlinelibrary.wiley.com/doi/10.1002/ijc.23584/full
Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB2 (full–2009) http://www.nature.com/bjc/journal/v101/n6/full/6605248a.html
Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism (full-2009)  http://mcr.aacrjournals.org/content/7/7/1086.long
Cannabinoid Receptor Activation Protects Coronary Endothelium Against Reperfusion Induced Intercellular Gap Formation in a Cellular Model of Ischemia and Reperfusion (abst–2009) http://circ.ahajournals.org/cgi/content/meeting_abstract/120/18_MeetingAbstracts/S1072-c?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=720&resourcetype=HWCIT
The cannabinoid R+ methanandamide induces IL-6 secretion by prostate cancer PC3 cells (abst-2009) http://www.ncbi.nlm.nih.gov/pubmed/19908944
R(+)-methanandamide-induced apoptosis of human cervical carcinoma cells involves a cyclooxygenase-2-dependent pathway (abst–2009) http://www.ncbi.nlm.nih.gov/pubmed/19015962


RWJ-400065
Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors (full-2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189718/?tool=pubmed


SAB-378
CB1 receptors mediate the analgesic effects of cannabinoids on colorectal distension-induced visceral pain in rodents (full–2007) http://www.jneurosci.org/content/29/5/1554.long
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration (abst–2007) http://www.ncbi.nlm.nih.gov/pubmed/17630726


SPICE-NEWS
Synthetic cannabis mimic found in herbal incense (news–2009) http://www.rsc.org/chemistryworld/News/2009/January/15010901.asp


SR-144528
p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells (full–2005) http://www.sciencedirect.com/science/article/pii/S0014579305010057
Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor (full–2006) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1616976/
The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway (abst–2006) http://www.ncbi.nlm.nih.gov/pubmed/16624285
CB1 receptors mediate the analgesic effects of cannabinoids on colorectal distension-induced visceral pain in rodents (full–2007) http://www.jneurosci.org/content/29/5/1554.long


SURINABANT / SR 147778
SR147778 [5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a New Potent and Selective Antagonist of the CB1 Cannabinoid Receptor: Biochemical and Pharmacological Characterization (full–2004) http://jpet.aspetjournals.org/content/310/3/905.long
Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats (full–2005) http://alcalc.oxfordjournals.org/content/40/1/46.long
SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats (abst–2006) http://www.ncbi.nlm.nih.gov/pubmed/17127132
Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats (abst–2008) http://www.ncbi.nlm.nih.gov/pubmed/17720206
top


Advertisements